Day One Biopharmaceuticals reported beneficial ownership of 5.44% of its common stock, equal to 5,615,390 shares, as disclosed on 03/12/2026. The position is held by funds managed by Glazer Capital, LLC and is reported jointly by Glazer Capital and Paul J. Glazer. The filing states that Glazer Capital Enhanced Master Fund, Ltd., a Glazer Fund, has the right to receive proceeds from the sale of more than 5% of the outstanding common stock.
Positive
None.
Negative
None.
Insights
Glazer Capital reports a passive, >5% stake held through managed funds.
Glazer Capital, LLC and Paul J. Glazer jointly report beneficial ownership of 5,615,390 shares, representing 5.44% of common stock. The filing is a Schedule 13G disclosure, which typically indicates passive investment intent rather than an active control stake.
The statement identifies Glazer Capital Enhanced Master Fund, Ltd. as having the right to receive sale proceeds for a >5% holding. Timing and any planned transactions are not disclosed in the excerpt.
Disclosure clarifies ownership and voting/dispositive power is shared across the Glazer-managed accounts.
The report lists 0 shares with sole voting or dispositive power and 5,615,390 shares with shared voting and dispositive power. This allocation reflects management of holdings on behalf of multiple Glazer Funds rather than individual direct control.
Subsequent filings would disclose any change in stake or trading activity; this excerpt contains the snapshot reported as of the stated date.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
DAY ONE BIOPHARMACEUTICALS, INC.
(Name of Issuer)
Common Stock, par value $0.0001 per share
(Title of Class of Securities)
23954D109
(CUSIP Number)
03/12/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
23954D109
1
Names of Reporting Persons
Glazer Capital, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
5,615,390.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
5,615,390.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
5,615,390.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.4 %
12
Type of Reporting Person (See Instructions)
IA, OO
SCHEDULE 13G
CUSIP Number(s):
23954D109
1
Names of Reporting Persons
Paul J. Glazer
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
5,615,390.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
5,615,390.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
5,615,390.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.4 %
12
Type of Reporting Person (See Instructions)
IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
DAY ONE BIOPHARMACEUTICALS, INC.
(b)
Address of issuer's principal executive offices:
1800 Sierra Point Parkway, Suite 200, Brisbane, CALIFORNIA, 94005.
Item 2.
(a)
Name of person filing:
This statement is filed by:
(i) Glazer Capital, LLC, a Delaware limited liability company ("Glazer Capital"), with respect to the shares of Common Stock (as defined in Item 2(d)) held by certain funds and managed accounts to which Glazer Capital serves as investment manager (collectively, the "Glazer Funds"); and
(ii) Mr. Paul J. Glazer ("Mr. Glazer"), who serves as the Managing Member of Glazer Capital, with respect to the shares of Common Stock held by the Glazer Funds.
The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."
The filing of this statement should not be construed as an admission that any of the Reporting Persons is, for the purposes of Section 13 of the Act, the beneficial owner of the shares of Common Stock (as defined in Item 2(d)) reported herein.
(b)
Address or principal business office or, if none, residence:
The address of the business office of each of the Reporting Persons is 250 West 55th Street, Suite 30A, New York, New York 10019.
(c)
Citizenship:
Glazer Capital is a Delaware limited liability company. Mr. Glazer is a United States citizen.
(d)
Title of class of securities:
Common Stock, par value $0.0001 per share
(e)
CUSIP Number(s):
23954D109
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
5,615,390
(b)
Percent of class:
5.44%
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
0
(ii) Shared power to vote or to direct the vote:
5,615,390
(iii) Sole power to dispose or to direct the disposition of:
0
(iv) Shared power to dispose or to direct the disposition of:
5,615,390
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
See Item 2. Glazer Capital Enhanced Master Fund, Ltd., a Glazer Fund, has the right to receive or the power to direct the receipt of the proceeds from the sale of more than 5% of the shares of Common Stock outstanding.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
What stake does Glazer Capital report in Day One Biopharmaceuticals (DAWN)?
Glazer Capital reports beneficial ownership of 5,615,390 shares, equal to 5.44% of common stock, as disclosed in the Schedule 13G filing dated 03/12/2026. The shares are held through Glazer-managed funds.
Who filed the Schedule 13G for DAWN and why?
The filing was made by Glazer Capital, LLC and Paul J. Glazer to report holdings of Glazer-managed funds. Schedule 13G disclosures are typically used to report passive investment positions exceeding 5% ownership.
Does Glazer Capital have sole voting or dispositive power over these DAWN shares?
No. The filing reports 0 shares with sole voting or dispositive power and 5,615,390 shares with shared voting and dispositive power, indicating management through collective fund arrangements.
Which Glazer fund can receive proceeds from a sale of DAWN shares?
Glazer Capital Enhanced Master Fund, Ltd. is named as having the right to receive proceeds from the sale of more than 5% of the outstanding common stock, per the Schedule 13G excerpt.
Does this Schedule 13G indicate an intent to control Day One Biopharmaceuticals?
The Schedule 13G filing format and the reporting language indicate a passive position held by Glazer-managed funds; it does not state an intent to control the company or seek active control in this excerpt.
